Ocular Therapeutix Inc logo

OCUL

Ocular Therapeutix Inc

$5.23

Earnings Summary

Revenue
$13.19Mn
Net Profits
$-12.54Mn
Net Profit Margins
-95.11%

Highlights

Revenue:

Ocular Therapeutix Inc’s revenue jumped 79.61% since last year same period to $13.19Mn in the Q1 2022. On a quarterly growth basis, Ocular Therapeutix Inc has generated 7.13% jump in its revenue since last 3-months.

Net Profits:

Ocular Therapeutix Inc’s net profit fell -501.86% since last year same period to $-12.54Mn in the Q1 2022. On a quarterly growth basis, Ocular Therapeutix Inc has generated -225.77% fall in its net profits since last 3-months.

Net Profit Margins:

Ocular Therapeutix Inc’s net profit margin fell -323.74% since last year same period to -95.11% in the Q1 2022. On a quarterly growth basis, Ocular Therapeutix Inc has generated -204.08% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ocular Therapeutix Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.23
EPS Estimate Current Year
-0.23

Highlights

EPS Estimate Current Quarter:

Ocular Therapeutix Inc’s earning per share (EPS) estimates for the current quarter stand at -0.23 - a 11.54% jump from last quarter’s estimates.

EPS Estimate Current Year:

Ocular Therapeutix Inc’s earning per share (EPS) estimates for the current year stand at -0.23.

Key Ratios

Key ratios of the Ocular Therapeutix Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.16
Return on Assets (ROA)
-0.23
Return on Equity (ROE)
-0.45
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Ocular Therapeutix Inc’s earning per share (EPS) fell -500% since last year same period to -0.16 in the Q1 2022. This indicates that the Ocular Therapeutix Inc has generated -500% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ocular Therapeutix Inc’s return on assets (ROA) stands at -0.23.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ocular Therapeutix Inc’s return on equity (ROE) stands at -0.45.

Dividend Per Share (DPS):

Ocular Therapeutix Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.26
-0.16
38.46%

Company Information

Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix's first commercial drug product, DEXTENZA (dexamethasone ophthalmic insert) 0.4 mg for intracanalicular use, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix has also submitted a Supplemental NDA for DEXTENZA to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. Ocular Therapeutix's earlier stage development assets currently in Phase 1 clinical trials include OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases and OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. Ocular Therapeutix is currently evaluating each of OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease in Phase 2 clinical trials. Also, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) is in pre-clinical development as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix's first product, ReSure® Sealant is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.

Organisation
Ocular Therapeutix Inc
Headquarters
Bedford, Massachusetts, US
Employees
181
Industry
Health Technology
CEO
Antony Mattessich